Open an account

Atrium Therapeutics

RNA · NASDAQ

$7.98+$0.37 (+4.86%)TodayMarket closed ·
Prev close $7.61

About RNA

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. The company is headquartered in San Diego, California and currently employs 47 full-time employees. The company went IPO on 2026-02-27. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. The company is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Employees
47
Headquarters
San Diego, California
Listed
Feb 27, 2026
Sector
Health Care
Industry
Biotechnology

RNA key statistics

Market cap
177.76M
Price-earnings ratio
-14.65
Dividend yield
—
Average volume
3.50M
Volume
289.50K
Open price
$7.75
High today
$8.27
Low today
$7.71
52 Week high
$73.06
52 Week low
$7.49

Atrium Therapeutics (RNA) at a glance

Atrium Therapeutics (RNA) last traded at $7.98, with a market cap of 177.76M and a price-to-earnings ratio of -14.65.

Today the stock has traded between $7.71 and $8.27. The current price is 3.5% above the day's low and 3.5% below its high.

Volume so far is 289.50K shares, below the average of 3.50M shares a day.

Over the past year Atrium Therapeutics has ranged from $7.49 to $73.06, and now sits 1% of the way up that range.

Atrium Therapeutics met or beat analyst EPS estimates in 2 of the last 2 quarters. In Q2 FY26 it reported -$1.18 per share against an estimate of -$1.43.

The average analyst price target is $25.50, 219.5% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 12 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 5 analystsAvg $25.50
Low
$25.25
Now
$7.98
High
$26.25

RNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 2 quarters, by 13.1% on average.

  1. Q1 FY26: reported -$0.97 per share against an estimate of -$1.06
  2. Q2 FY26: reported -$1.18 per share against an estimate of -$1.43

RNA news

  • Press releasePRNewswire

    Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

  • Press releasePRNewswire

    Atrium Therapeutics Announces $50 Million Private Placement

  • Press releasePRNewswire

    Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    Atrium Therapeutics to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    Atrium Therapeutics Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Similar companies

Companies in the same industry as Atrium Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.